image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 290.1
1.04 %
$ 8.77 B
Market Cap
22.97
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MEDP stock under the worst case scenario is HIDDEN Compared to the current market price of 290 USD, Medpace Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MEDP stock under the base case scenario is HIDDEN Compared to the current market price of 290 USD, Medpace Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one MEDP stock under the best case scenario is HIDDEN Compared to the current market price of 290 USD, Medpace Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MEDP

image
$370.0$370.0$360.0$360.0$350.0$350.0$340.0$340.0$330.0$330.0$320.0$320.0$310.0$310.0$300.0$300.0$290.0$290.0$280.0$280.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.11 B REVENUE
11.84%
447 M OPERATING INCOME
32.67%
404 M NET INCOME
42.99%
609 M OPERATING CASH FLOW
40.48%
-28.3 M INVESTING CASH FLOW
18.25%
-154 M FINANCING CASH FLOW
15.68%
537 M REVENUE
0.61%
125 M OPERATING INCOME
11.67%
117 M NET INCOME
21.36%
191 M OPERATING CASH FLOW
27.90%
-7.56 M INVESTING CASH FLOW
27.88%
-169 M FINANCING CASH FLOW
-2687.42%
Balance Sheet Medpace Holdings, Inc.
image
Current Assets 1.03 B
Cash & Short-Term Investments 669 M
Receivables 296 M
Other Current Assets 63.4 M
Non-Current Assets 1.07 B
Long-Term Investments 0
PP&E 252 M
Other Non-Current Assets 819 M
31.86 %14.11 %3.02 %12.01 %39.00 %Total Assets$2.1b
Current Liabilities 1.1 B
Accounts Payable 32.5 M
Short-Term Debt 0
Other Current Liabilities 1.07 B
Non-Current Liabilities 171 M
Long-Term Debt 126 M
Other Non-Current Liabilities 44.5 M
84.06 %9.90 %3.49 %Total Liabilities$1.3b
EFFICIENCY
Earnings Waterfall Medpace Holdings, Inc.
image
Revenue 2.11 B
Cost Of Revenue 1.45 B
Gross Profit 656 M
Operating Expenses 209 M
Operating Income 447 M
Other Expenses 42.5 M
Net Income 404 M
3b3b2b2b2b2b1b1b500m500m002b(1b)656m(209m)447m(42m)404mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
31.12% GROSS MARGIN
31.12%
21.19% OPERATING MARGIN
21.19%
19.17% NET MARGIN
19.17%
48.98% ROE
48.98%
19.25% ROA
19.25%
38.11% ROIC
38.11%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Medpace Holdings, Inc.
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 404 M
Depreciation & Amortization 29.3 M
Capital Expenditures 0
Stock-Based Compensation 25.5 M
Change in Working Capital 157 M
Others 177 M
Free Cash Flow 609 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Medpace Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for MEDP of $406 , with forecasts ranging from a low of $330 to a high of $469 .
MEDP Lowest Price Target Wall Street Target
330 USD 13.75%
MEDP Average Price Target Wall Street Target
406 USD 39.99%
MEDP Highest Price Target Wall Street Target
469 USD 61.67%
Price
Max Price Target
Min Price Target
Average Price Target
480480460460440440420420400400380380360360340340320320300300280280May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Medpace Holdings, Inc.
image
Sold
0-3 MONTHS
1.38 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.47 M USD 1
9-12 MONTHS
64.2 M USD 2
Bought
652 USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit. fool.com - 2 weeks ago
Medpace Holdings: It Might Be Time To Buy In Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties around pharmaceutical spending and backlogs, which could make the current valuation appear too high. seekingalpha.com - 2 weeks ago
Medpace (MEDP) Outperforms Broader Market: What You Need to Know Medpace (MEDP) closed at $330.59 in the latest trading session, marking a +1.96% move from the prior day. zacks.com - 3 weeks ago
CON or MEDP: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 3 weeks ago
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025 CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 1. businesswire.com - 1 month ago
CON vs. MEDP: Which Stock Is the Better Value Option? Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 1 month ago
Medpace (MEDP) Advances While Market Declines: Some Information for Investors Medpace (MEDP) concluded the recent trading session at $324.13, signifying a +1.55% move from its prior day's close. zacks.com - 1 month ago
An Investigation Has Been Launched Into Medpace Holdings, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
An Investigation Has Been Launched Into Medpace Holdings, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
An Investigation Has Been Launched Into Medpace Holdings, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. accessnewswire.com - 1 month ago
8. Profile Summary

Medpace Holdings, Inc. MEDP

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 8.77 B
Dividend Yield 0.00%
Description Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Contact 5375 Medpace Way, Cincinnati, OH, 45227 https://www.medpace.com
IPO Date Aug. 11, 2016
Employees 5900
Officers Mr. Weimin Gai MS Senior Vice President of Biometrics Dr. August James Troendle M.D. Chairman & Chief Executive Officer Mr. Todd Meyers Vice President of Business Development & Marketing Ms. Susan E. Burwig BSN, MA Executive Vice President of Operations